



# Potential ways to address antimicrobial resistance across India and wider exacerbated by COVID-19

Mainul Haque<sup>1</sup> , Johanna C. Meyer<sup>2</sup> , Brian Godman<sup>2,3,4\*</sup> 

Rising rates of antimicrobial resistance (AMR) are a concern across all countries as AMR increases morbidity, mortality and costs (Cassini *et al.*, 2019, Founou *et al.*, 2017, Godman *et al.*, 2021a, Haque and Godman, 2021a, Hofer, 2019, Shrestha *et al.*, 2018, Swaminathan *et al.*, 2017). The World Bank in 2017 believed even in a low-AMR scenario, the loss on output as a result of AMR across the world could exceed US\$1 trillion annually after 2030 unless addressed, which is equivalent to 3.8% of annual Gross Domestic Product (GDP) (World Bank, 2017). In addition, the overall costs of AMR appreciably exceed those of any of the antibiotics prescribed or dispensed (Shrestha *et al.*, 2018). It is also estimated that in India there will be more than two million deaths a year due to AMR by 2050 unless the factors causing AMR, including excessive and inappropriate use of antibiotics, are addressed (Chandra *et al.*, 2020).

The concerns with rising AMR rates have resulted in multiple activities by the World Health Organization (WHO) and others, including the development of national action plans (NAP) as well as the classification of antibiotics into Access, Watch, or Reserve (AWaRe) antibiotics in the WHO Essential Medicines List (EML), to guide and assess the quality of antimicrobial utilization (Gandra and Kotwani, 2019, Rogers Van Katwyk *et al.*, 2019, Saleem *et al.*, 2020, Seale *et al.*, 2017, Sharland *et al.*, 2019, Skosana *et al.*, 2021, World Health Organization, 2015, World Health Organization, 2018). India is no exception. National activities include instigating AMR surveillance networks in 2013, launching national treatment guidelines directing antimicrobial use in infectious diseases in 2016 and publishing its own NAP on AMR in 2017 (Chandra *et al.*, 2020, Government of India, 2017, National Centre for Disease Control, 2016, Swaminathan *et al.*, 2017). More recent initiatives in India include the introduction of national guidelines on Infection, Prevention and Control among healthcare facilities in 2020 as well as encouraging antimicrobial stewardship programs (ASPs) via a series of training workshops (Ministry of Health and Family Welfare 2020, Ministry of Health and Family Welfare, 2021a).

These programs are seen as essential given current concerns with AMR rates in India exacerbated by the current consumption of antimicrobials in India being among the highest in the world (Gandra and Kotwani, 2019). ASPs have been successful in hospitals even in low- and middle-income countries (LMICs), with their greater pressure on resources (Cox *et al.*, 2017), to improve antibiotic use. This includes programs to stop the prolonged administration of antibiotics to prevent surgical site infections as well as other targets (Ahmed *et al.*, 2018, Akpan, 2020; Godman *et al.*, 2021a, Majumder *et al.*, 2020, Mwita *et al.*, 2021, Nathwani *et al.*, 2019). We are

---

<sup>1</sup>Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Sungai Besi, 57000 Kuala Lumpur, Malaysia. Email: [runurono@gmail.com](mailto:runurono@gmail.com)

<sup>2</sup>Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Gauteng, South Africa. Emails: [hannelie.meyer@smu.ac.za](mailto:hannelie.meyer@smu.ac.za); [brian.godman@smu.ac.za](mailto:brian.godman@smu.ac.za)

<sup>3</sup>Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom. Email: [Brian.Godman@strath.ac.uk](mailto:Brian.Godman@strath.ac.uk)

<sup>4</sup>School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.

\*For correspondence: Brian Godman, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom. Email: [Brian.Godman@strath.ac.uk](mailto:Brian.Godman@strath.ac.uk), Telephone: 0141 548 3825. Fax: 0141 552 2562

also seeing successful programs introduced in ambulatory care, including LMICs, to reduce unnecessary prescribing and dispensing of antibiotics for essentially viral infections such as respiratory tract infections (Godman *et al.*, 2021a, Godman *et al.*, 2020a, Haque and Godman, 2021b). However, multiple activities are still needed given continual concerns with AMR rates and the lack of new antibiotics being developed (O'Neill, 2015).

The COVID-19 pandemic has further exacerbated the inappropriate use of antimicrobials across countries (Langford *et al.*, 2021). This includes the increasing use of hydroxychloroquine among countries following the initial hype, leading to shortages, price rises and deaths (Abena *et al.*, 2020, Haque *et al.*, 2021a, Haque *et al.*, 2021b, Sefah *et al.*, 2021). However, this was not the case in ambulatory care in countries where there were regulations outlawing the purchasing of antibiotics without a prescription and these were being followed, including Namibia and Vietnam, or where pharmacists in dispensaries provided appropriate guidance on managing COVID-19 including symptomatic relief such as Kenya (Godman *et al.*, 2020b, Kibuule *et al.*, 2021, Opanga *et al.*, 2021). This was encouraging as the well-constructed Solidarity (WHO) and UK Recovery trials showed no clinical benefit from using hydroxychloroquine in the management of patients with COVID-19; consequently, no longer recommended (Abubakar *et al.*, 2021, Horby *et al.*, 2020, Rochwerg *et al.*, 2020, World Health Organization, 2020). Interestingly in India, sales of hydroxychloroquine peaked in March 2020 but slowed down thereafter as more clinical trial data became available (Sulis *et al.*, 2021).

There has also been increasing use of antibiotics including azithromycin across health care sectors and countries, including India, as a result of the pandemic (Langford *et al.*, 2021, Sulis *et al.*, 2021). Published studies have suggested that up to 70% or more of patients with COVID-19 received antibiotics as part of their management (Knight *et al.*, 2021, Langford *et al.*, 2021, Rawson *et al.*, 2020), with appreciable over-use also recorded in India (Gale and Shrivastava, 2021). This includes azithromycin (Sulis *et al.*, 2021), with such overuse of antimicrobials likely to drive up AMR rates (Hsu, 2020, Saini *et al.*, 2021). This is despite less than 10% of patients with COVID-19 appearing to have either bacterial or fungal infections (Hsu, 2020), with some studies suggesting as few as 3.2% of patients with COVID-19 warrant an antibiotic (Langford *et al.*, 2021, Sriram *et al.*, 2021). This is similar to the findings of Rajni *et al.* (2021), who found that out of 1578 COVID-19 positive patients that were admitted to their tertiary hospital in India over a 5-month period, only 9.4% of the blood cultures were positive out of the 158 blood cultures taken (Rajni *et al.*, 2021).

Potential ways forward in India and wider to reduce AMR include assessing the current situation regarding antimicrobial use in hospitals. Subsequently, using the findings to instigate appropriate ASPs in line with national recommendations. This strategy is motivated by the fact that whilst national guidelines advocate prudent use of antimicrobials among adult patients with suspected or actual COVID-19 in hospitals, there is currently a dearth of publications documenting their use among admitted patients in India. This includes assessing patient management, including antimicrobials, against national or local guidelines with only a limited number of patients likely to have either bacterial or fungal co-infections (Government of India, 2021, Rajni *et al.*, 2021, Langford *et al.*, 2021). This is a concern since, as mentioned, adherence to agreed guidelines is increasingly seen as good quality prescribing resulting in a reduction of inappropriate antibiotic utilization in hospitals (Campbell *et al.*, 2021, Godman *et al.*, 2021a, Mwita *et al.*, 2021, Versporten *et al.*, 2018).

However, we are aware that there can be secondary infections among patients admitted to hospitals in India with COVID-19, which requires active ASPs to monitor and improve their future outcomes as well as reduce resistance rates (Khurana *et al.*, 2021, Saini *et al.*, 2021). Overall though, in the study by Vijay *et al.* (2021), out of 17,534 admitted patients to hospitals in India, only 3.6% developed secondary fungal or bacterial infections (Vijay *et al.*, 2021). There has also been limited research to date regarding the management of children with COVID-19 admitted to hospitals in India, although guidelines have also been published (Ministry of Health and Family Welfare, 2021b, Sankar *et al.*, 2020). We are aware of the high use of antimicrobials among hospitalized children with COVID-19 in Bangladesh, and we will be investigating this further in India to provide future guidance (Nusrat *et al.*, 2021).

Instigating vaccination programs with effective vaccines, including booster doses, is also seen a critical step to reduce hospitalizations, as well as the unnecessary use of antimicrobials, in patients with COVID-19, given concerns with AMR rates in India (Lopez Bernal *et al.*, 2021a, Lopez Bernal *et al.*, 2021b, Iheanacho *et al.*, 2021, Majumder *et al.*, 2020). This builds on previous findings with other vaccines that reduced subsequent antimicrobial utilization and AMR (Buchy *et al.*, 2020, Godman *et al.*, 2021a, Jansen and Anderson, 2018, Lewnard *et al.*, 2020, Troisi *et al.*, 2020). However, there are real concerns with vaccine hesitancy towards COVID-19 vaccines across countries, including India, fueled by the spread of misinformation (Danabal *et al.*, 2021, Khan *et al.*, 2020, Sallam *et al.*, 2021, Wilson and Wiysonge, 2020). Overall vaccine hesitancy rates do appear to be higher in some high-income countries versus LMICs; however, this is not always the

case (Solís Arce *et al.*, 2021, Lazarus *et al.*, 2021). Consequently, it is critical that any misinformation regarding COVID-19 vaccines is rapidly addressed through various channels, including from Governments, healthcare associations and patient groups, with the positive help of social media messaging, harnessed to increase confidence and use of vaccines. This can include making vaccinations easy to access and inducing feelings of ownership among those vaccinated (Dai *et al.*, 2021). Alongside this, ensuring access to effective vaccines by making them free-of-charge (BBC News, 2021).

In ambulatory care, we have seen that multiple coordinated activities have reduced antimicrobial utilization as well as limited any increase among countries where there is already low antimicrobial utilization (Abilova *et al.*, 2018, Furst *et al.*, 2015, Bojanic *et al.*, 2018, Godman *et al.*, 2020b, Wilkinson *et al.*, 2018). This contrasts with Poland where the authorities and other groups have only instigated limited activities. This resulted in Poland having one of the highest rates of antibiotic consumption across Europe between 2007 and 2016 (Wojkowska-Mach *et al.*, 2018). Similarly, multiple activities including education, removal of licenses to practice, and potentially fines, have reduced the extent of inappropriate prescribing and self-purchasing of antibiotics without a prescription in numerous studies (Alrasheedy *et al.*, 2020, Godman *et al.*, 2020a, Godman *et al.*, 2021a, Godman *et al.*, 2021b, Haque and Godman, 2021b, Jacobs *et al.*, 2019). This is similar to the situation in other disease areas and circumstances providing direction to the Government in India and elsewhere (Godman *et al.*, 2021b, Godman, 2021, Godman *et al.*, 2021c, Kroon *et al.*, 2021).

In conclusion, we have seen that the inappropriate use of antimicrobials has risen across countries, including India, during the current COVID-19 pandemic. This urgently needs to be addressed to reduce current AMR rates and their impact on morbidity, mortality and costs. There are a number of coordinated strategies that key stakeholder groups, including Governments, can undertake to improve the future use of antimicrobials during pandemics, and other circumstances, to address concerns with rising AMR rates. Typically, multiple strategies have greater impact. Furthermore, effective programs to prevent vaccine-preventable diseases, as well as the associated reduction in antimicrobial use, should be expedited along with programs to reduce vaccine hesitancy in the community. These activities can build on agreed NAPs and other national activities to reduce AMR. We will continue to monitor the situation.

## CONFLICTS OF INTEREST

The authors declare they have no relevant conflicts of interest.

## FUNDING

This Editorial was self-funded.

## REFERENCES

- Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, Muyembe Tamfum JJ, Seydi M, Eholie SP, Mills EJ, Kallay O, Zumla A, Nachege JB. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. *Am J Trop Med Hyg*, 2020; 102, 1184-1188. <https://doi.org/10.4269/ajtmh.20-0290>
- Abilova V, Kurdi A, Godman B. Ongoing initiatives in Azerbaijan to improve the use of antibiotics; findings and implications, *Expert Review of Anti-infective Therapy*, 2018;16:1, 77-84, [HTTPS://DOI.ORG/10.1080/14787210.2018.1417835](https://doi.org/10.1080/14787210.2018.1417835)
- Abubakar AR, Sani IH, Godman B, Kumar S, Islam S, Jahan I, Haque M. Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. *Infect Drug Resist*, 2020;13:4673-4695. <https://doi.org/10.2147/IDR.S289037>
- Ahmed SA, Kumar A, Sethi P, Kapil A, Pandey RM, Wig N. Effectiveness of education and antibiotic control program at All India Institute of Medical Sciences, New Delhi. *Natl Med J India*. 2018;31(5):262-267. <https://doi.org/10.4103/0970-258X.261176>
- Akpan MR, Isemin NU, Udoh AE & Ashiru-Oredope, D. Implementation of antimicrobial stewardship programmes in African countries: a systematic literature review. *J Glob Antimicrob Resist*, 2020;22, 317-32
- Alrasheedy AA, Alsalloum MA, Almuqbil FA, Almuzaini MA, Aba Alkhayl BS, Albishri AS, Alharbi FF, Alharbi SR, Alodhayb AK, Alfadl AA, Godman B, Hill R, Anaam MS. The impact of law enforcement on dispensing antibiotics without prescription: a multi-methods study from Saudi Arabia. *Expert Rev Anti Infect Ther*, 2020;18(1):87-97. <https://doi.org/10.1080/14787210.2020.1705156>
- BBC News. Covid vaccine: India gives 20 million jabs to mark PM Modi's birthday. 17 September 2021. Available at URL: <https://www.bbc.co.uk/news/world-asia-india-56345591> [Accessed 22 September 2021]
- Bojanić L, Marković-Peković V, Škrbić R, Stojaković N, Dermanović M, Bojanić J, Furst J, Kurdi AB, Godman B. Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. *Front Pharmacol*, 2018;29:9:442. <https://doi.org/10.4103/0970-258X.261176>
- Buchy P, Ascioğlu S, Buisson Y, Datta S, Nissen M, Tambyah PA, Vong S. Impact of vaccines on antimicrobial resistance. *Int J Infect Dis*. 2020;90:188-196. <https://doi.org/10.1016/j.ijid.2019.10.005>
- Campbell SM, Meyer JC, Godman B. Why Compliance to National Prescribing Guidelines is Important Especially across Sub-Saharan Africa and Suggestions for the Future. *J Biomed Pharm Sci*, 2021; 4: 309
- Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleeschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C & Monnet DL. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant

bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis.* 2019;19, 56-66. [https://doi.org/10.1016/S1473-3099\(18\)30605-4](https://doi.org/10.1016/S1473-3099(18)30605-4)

Chandra S, Prithvi P P, Srija K, Jauhari S, Grover A. Antimicrobial resistance: Call for rational antibiotics practice in India. *J Family Med Prim Care* [serial online] 2020 [cited 2021 Oct 1];9:2192-9. [https://doi.org/10.4103/jfmipc.jfmipc.1077\\_19](https://doi.org/10.4103/jfmipc.jfmipc.1077_19)

Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV, Gould I & Levy HG. Antibiotic stewardship in low- and middle-income countries: the same but different? *Clin Microbiol Infect.* 2017;23, 812-818. <https://doi.org/10.1016/j.cmi.2017.07.010>

Dai H, Saccardo S, Han MA, Roh L, Raja N, Vangala S, Modi H, Pandya S, Sloyan M & Croymans DM. Behavioural nudges increase COVID-19 vaccinations. *Nature.* 2021;597, 404-409. <https://doi.org/10.1038/s41586-021-03843-2>

Danabal KGM, Magesh SS, Saravanan S. *et al.* Attitude towards COVID 19 vaccines and vaccine hesitancy in urban and rural communities in Tamil Nadu, India – a community based survey. *BMC Health Serv Re.* 2021;21, 994. <https://doi.org/10.1186/s12913-021-07037-4>

Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. *PLoS ONE.* 2017;12(12): e0189621. <https://doi.org/10.1371/journal.pone.0189621>

Furst J, Cizman M, Mrak J, Kos D, Campbell S, Coenen S, Gustafsson LL, Furst L & Godman B. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. *Expert Rev Anti Infect Ther.* 2015;13, 279-89. <https://doi.org/10.1586/14787210.2015.990381>

Gale J, Shrivastava B. Antibiotics for Covid Cases Worsen India's Superbug Crisis. 2021. Available at URL: <https://www.bloombergquint.com/coronavirus-outbreak/antibiotics-for-covid-patients-worsen-india-s-superbug-plight> [Accessed 27 September 2021]

Gandra S, Kotwani A. Need to improve availability of “access” group antibiotics and reduce the use of “watch” group antibiotics in India for optimum use of antibiotics to contain antimicrobial resistance. *J of Pharm Policy and Pract.* 2019;12, 20. <https://doi.org/10.1186/s40545-019-0182-1>

Godman B. Health authority activities to enhance the quality and efficiency of medicine use and their impact. *Adv Hum Biol* 2021;11:11-6 <https://doi.org/10.4103/2321-8568.308858>

Godman B, Haque M, McKimm J, Abu Bakar M, Sneddon J, Wale J, Campbell S, Martin AP, Hoxha I, Abilova V, Anand Paramadhas BD, Mpinda-Joseph P, Matome M, de Lemos LLP, Sefah I, Kurdi A, Opanga S, Jakupi A, Saleem Z, Hassali MA, Kibuule D, Fadare J, Bochenek T, Rothe C, Furst J, Markovic-Pekovic V, Bojanić L, Schellack N, Meyer JC, Matsebula Z, Phuong TNT, Thanh BN, Jan S, Kalungia A, Mtapuri-Zinyowera S, Sartelli M, Hill R. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. *Curr Med Res Opin.* 2020a;36(2):301-327. <https://doi.org/10.1080/03007995.2019.1700947>

Godman B, Haque M, Islam S, Iqbal S, Urmi U L, Kamal ZM, Shuvo SA, Rahman A, Kamal M, Haque M, Jahan I, Islam MZ, Hossain MM, Munzur-E-Murshid, Kumar S, Charan J, Bhatt R, Dutta S, Abhayanand JP, Sharma Y, Saleem Z, Phuong TNT, Kwon HY, Kurdi A, Wale J & Sefah I. Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. *Frontiers in Public Health.* 2020b;8. <https://doi.org/10.3389/fpubh.2020.585832>

Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, Saleem Z, Sneddon J, Hoxha I, Islam S, Mwita J, do Nascimento RCRM, Dias Godói IP, Niba LL, Amu AA, Acolatse J, Incoom R, Sefah IA, Opanga S, Kurdi A, Chikowe I, Khuluza F, Kibuule D, Ogunleye OO, Olalekan A, Markovic-Pekovic V, Meyer JC, Alfadl A, Phuong TNT, Kalungia AC, Campbell S, Pisana A, Wale J, Seaton RA. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. *Life.* 2021a;11(6):528. <https://doi.org/10.3390/life11060528>

Godman B, Fadare J, Kwon HY, Dias CZ, Kurdi A, Dias Godói IP, Kibuule D, Hoxha I, Opanga S, Saleem Z, Bochenek T, Marković-Peković V, Mardare I, Kalungia AC, Campbell S, Allocati E, Pisana A, Martin AP, Meyer JC. Evidence-based public policy making for medicines across countries: findings and implications for the future. *J Comp Eff Res.* 2021b;10(12):1019-52. <https://doi.org/10.2217/cer-2020-0273>

Godman B, Massele A, Fadare J, Kwon H-Y, Kurdi A, Kalemeera F *et al.* Generic Drugs – Essential for the Sustainability of Healthcare Systems with Numerous Strategies to Enhance their Use. *Pharmaceutical Sciences And Biomedical Analysis Journal.* 2021c; 4(1):126.

Government of India. National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017 – 2021. 2017. Available at URL: [https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/national-action-plan-on-amr-\(india\).pdf?sfvrsn=9f396e90\\_1&download=true](https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/national-action-plan-on-amr-(india).pdf?sfvrsn=9f396e90_1&download=true) [Accessed 23 September 2021]

Government of India Ministry of Health and Family Welfare. Clinical Management Protocol for COVID-19 (In Adults). Version 6. 2021. Available at URL: <https://cdnbbsr.s3waas.gov.in/s3850af92f8d9903e7a4e0559a98ecc857/uploads/2021/05/2021052587.pdf> [Accessed 23 September 2021]

Haque M, Abubakar AR, Ogunleye OO, Sani IH, Sefah I, Kurdi A, Islam S, Godman B. Changes in Availability, Utilization, and Prices of Medicines and Protection Equipment for COVID-19 in an Urban Population of Northern Nigeria. *J Res Pharm Pract.* 2021a; 10(1):17-22. [https://doi.org/10.4103/jrpp.JRPP\\_20\\_92](https://doi.org/10.4103/jrpp.JRPP_20_92)

Haque M, Kumar S, Charan J, Bhatt R, Islam S, Dutta S, Abhayanand JP, Sharma Y, Sefah I, Kurdi A, Wale J, Godman B. Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. *Front Pharmacol.* 2021b;11:582154. <https://doi.org/10.3389/fphar.2020.582154>

Haque M, Godman B. Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries. *Bangladesh Journal of Medical Science.* 2021a; 19 (3): 355-7. <https://doi.org/10.3329/bjms.v20i3.52787>

Haque M, Godman B. Potential strategies to reduce inappropriate prescribing and dispensing of antimicrobials in Bangladesh building on the experiences in other developing countries. *Bangladesh Journal of Medical Science*. 2021b; 20 (4): 700-6. <https://doi.org/10.3329/bjms.v20i4.54123>

Hofer, U. 2019. The cost of antimicrobial resistance. *Nat Rev Microbiol*, 17, 3. <https://doi.org/10.1038/s41579-019-0152-2>

Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, LIM WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R & Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020; 383, 2030-2040.

HSU J. How covid-19 is accelerating the threat of antimicrobial resistance. *Bmj*. 2020; 369, m1983. <https://doi.org/10.1136/bmj.m1983>

Iheanacho CO, Eze UIH, Adida EA. A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population. *Bull Natl Res Cent*. 2021;45(1):150. <https://doi.org/10.1186/s42269-021-00607-w>

Jacobs TG, Robertson J, van den Ham HA, Iwamoto K, Bak Pedersen H, Mantel-Teeuwisse AK. Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review. *BMC Health Serv Res*. 2019;19(1):536. <https://doi.org/10.1186/s12913-019-4359-8>

Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR). *Hum Vaccin Immunother*. 2018;14(9):2142-49. <https://doi.org/10.1080/21645515.2018.1476814>

Khan YH, Mallhi TH, Alotaibi NH, Alzarea AI, Alanazi AS, Tanveer N, Hashmi FK. Threat of COVID-19 Vaccine Hesitancy in Pakistan: The Need for Measures to Neutralize Misleading Narratives. *Am J Trop Med Hyg*. 2020;103(2):603-604. <https://doi.org/10.4269/ajtmh.20-0654>

Khurana S, Singh P, Sharad N, Kiro VV, Rastogi N, Lathwal A, Malhotra R, Trikha A, Mathur P. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. *Indian J Med Microbiol*. 2021;39(2):147-153. <https://doi.org/10.1016/j.ijmm.2020.10.014>

Kibuule D, Nambahu L, Sefah IA, Kurdi A, Phuong TNT, Kwon H-Y, Godman B. Activities in Namibia to Limit the Prevalence and Mortality from COVID-19 Including Community Pharmacy Activities and the Implications. *Sch Acad J Pharm*. 2021; 10(5): 82-92

Knight GM, Glover RE, McQuaid CF, Oлару ID, Gallandat K, Leclerc QJ, Fuller NM, Willcocks SJ, Hasan R, van Kleef E, Chandler CI. Antimicrobial resistance and COVID-19: Intersections and implications. *Elife*. 2021;10:e64139. <https://doi.org/10.7554/eLife.64139>

Kroon D, Steutel NF, Vermeulen H, Tabbers MM, Benninga MA, Langendam MW & Van Dulmen SA. Effectiveness of interventions aiming to reduce inappropriate drug prescribing: an overview of interventions. *Journal of Pharmaceutical Health Services Research*. 2021;12, 423-433. <https://doi.org/10.1093/jphsr/rmab038>

Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N, MacFadden DR. Antibiotic prescribing in

patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol Infect*. 2021;27(4):520-531. <https://doi.org/10.1016/j.cmi.2020.12.018>

Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med*. 2021 Feb;27(2):225-228. <https://doi.org/10.1038/s41591-020-1124-9>

Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R. Childhood vaccines and antibiotic use in low- and middle-income countries. *Nature*. 2020; 581(7806):94-99. <https://doi.org/10.1038/s41586-020-2238-4>

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021a;385(7):585-594. <https://doi.org/10.1056/NEJMoa2108891>

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ*. 2021b; 373, n1088. <https://doi.org/10.1136/bmj.n1088>

Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. *Infect Drug Resist*. 2020;13:4713-38. <https://doi.org/10.2147/IDR.S290835>

Ministry of Health and Family Welfare Government of India. NATIONAL GUIDELINES FOR INFECTION PREVENTION AND CONTROL IN HEALTHCARE FACILITIES. 2020. Available at URL: <https://www.mohfw.gov.in/pdf/National%20Guidelines%20for%20IPC%20in%20HCF%20-%20final%281%29.pdf> [Accessed 23 September 2021]

Ministry of Health and Family Welfare. Anti-Microbial Resistance Crisis. 2021a. Available at URL: <https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1703448> [Accessed 24 September 2021]

Ministry of Health & Family Welfare Government of India. Guidelines for Management of COVID-19 in Children (below 18 years). 2021b. Available at URL: <https://www.mohfw.gov.in/pdf/GuidelinesforManagementofCOVID19inCHILDREN18June2021final.pdf> [Accessed 24 September 2021]

Mwita JC, Ogunleye OO, Olalekan A, Kalungia AC, Kurdi A, Saleem Z, Sneddon J, Godman B. Key Issues Surrounding Appropriate Antibiotic Use for Prevention of Surgical Site Infections in Low- and Middle-Income Countries: A Narrative Review and the Implications. *Int J Gen Med*. 2021;14:515-530. <https://doi.org/10.2147/IJGM.S253216>

Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. *Antimicrob Resist Infect Control*. 2019;8:35. <https://doi.org/10.1186/s13756-019-0471-0>

NATIONAL CENTRE FOR DISEASE CONTROL - Directorate General of Health Services Ministry of Health & Family Welfare Government of India. National Treatment Guidelines for

Antimicrobial Use in Infectious Diseases. 2016. Available at URL: <https://ncdc.gov.in/WriteReadData/1892s/File622.pdf> [Accessed 23 September 2021]

Nusrat N, Haque M, Chowdhury K, Adnan N, Lutfur AB, Karim E *et al.* Pilot Study on the Current Management of Children with COVID-19 In Hospitals in Bangladesh; Findings and Implications. *Bangladesh Journal of Medical Science, Special Issue on COVID-19.* 2021; S188 - S198.

O'Neill J. Securing new drugs for future generations: the pipeline of antibiotics. The review of antimicrobial resistance. 2015. Available at URL: [https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB\\_0.pdf](https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf) [Accessed 22 September 2021]

Opanga SA, Rizvi N, Wamaita A, Sefah IA, Godman B. Availability of Medicines in Community Pharmacy to Manage Patients with COVID-19 in Kenya; Pilot Study and Implications. *Sch Acad J Pharm.* 2021; 10(3): 36-42

Rajni E, Garg VK, Bacchani D, Sharma R, Vohra R, Mamoria V, Malhotra H. Prevalence of Bloodstream Infections and their Etiology in COVID-19 Patients Admitted in a Tertiary Care Hospital in Jaipur. *Indian J Crit Care Med.* 202;25(4):369-373.

Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis.* 2020;71(9):2459-2468. <https://doi.org/10.1093/cid/ciaa530>

Rochweg B, Agarwal A, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, Lytvyn L, Leo YS, Macdonald H, Zeng L, Amin W, Burhan E, Bausch FJ, Calfee CS, Cecconi M, Chanda D, Du B, Geduld H, Gee P, Harley N, Hashimi M, Hunt B, Kabra SK, Kanda S, Kawano-Dourado L, Kim YJ, Kissoon N, Kwizera A, Mahaka I, Manai H, Mino G, Nsutebu E, Preller J, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Shankar-Hari M, Sharland M, Shen Y, Ranganathan SS, Souza JP, Stegemann M, De Sutter A, Ugarte S, Venkatapuram S, Dat VQ, Vuyiseka D, Wijewickrama A, Maguire B, Zeraatkar D, Bartoszko JJ, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Jacobs M, Vandvik PO. A living WHO guideline on drugs for covid-19. *BMJ.* 2020;370:m3379. <https://doi.org/10.1136/bmj.m3379>

Rogers Van Katwyk S, Grimshaw JM, Nkangu M, Nagi R, Mendelson M, Taljaard M, Hoffman SJ. Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map. *PLoS Med.* 2019;16(6):e1002819. <https://doi.org/10.1371/journal.pmed.1002819>

Saini V, Jain C, Singh NP, Alsulimani A, Gupta C, Dar SA, Haque S, Das S. Paradigm Shift in Antimicrobial Resistance Pattern of Bacterial Isolates during the COVID-19 Pandemic. *Antibiotics.* 2021;10(8):954. <https://doi.org/10.3390/antibiotics10080954>

Saleem Z, Hassali MA, Godman B, Fatima M, Ahmad Z, Sajid A, Rehman IU, Nadeem MU, Javaid Z, Malik M, Hussain A. Sale of WHO AWaRe groups antibiotics without a prescription in Pakistan: a simulated client study. *J Pharm Policy Pract.* 2020;13:26. <https://doi.org/10.1186/s40545-020-00233-3>

Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, Yaseen A, Ababneh NA, Bakri FG, Mahafzah A. High Rates

of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. *Vaccines.* 2021;9(1):42. <https://doi.org/10.3390/vaccines9010042>

Sankar J, Dhochak N, Kabra SK, Lodha R. COVID-19 in Children: Clinical Approach and Management. *Indian J Pediatr.* 2020;87(6):433-442. <https://doi.org/10.1007/s12098-020-03292-1>

Seale AC, Gordon NC, Islam J *et al.* AMR Surveillance in low and middle-income settings - A roadmap for participation in the Global Antimicrobial Surveillance System (GLASS) [version 1; peer review: 3 approved]. *Wellcome Open Res* 2017, 2:92 <https://doi.org/10.12688/wellcomeopenres.12527.1>

Sefah IA, Ogunleye OO, Essah DO, Opanga SA, Butt N, Wamaita A, Guantai AN, Chikowe I, Khuluza F, Kibuule D, Nambahu L, Abubakar AR, Sani IH, Saleem Z, Kalungia AC, Thi Phuong TN, Haque M, Islam S, Kumar S, Sneddon J, Wamboga J, Wale J, Miljković N, Kurdi A, Martin AP, Godman B. Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. *Front Pharmacol.* 2021;11:588106. <https://doi.org/10.3389/fphar.2020.588106>

Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, Mendelson M, Cappello B, Cooke G, Magrini N; EML Expert Committee and Antibiotic Working Group. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. *Lancet Infect Dis.* 2019;19(12):1278-1280. [https://doi.org/10.1016/S1473-3099\(19\)30532-8](https://doi.org/10.1016/S1473-3099(19)30532-8)

Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, Celhay O, Guerin PJ, Wertheim H, Lubell Y. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. *Antimicrob Resist Infect Control.* 2018;7:98. <https://doi.org/10.1186/s13756-018-0384-3>

Sriram A, Kalanxhi E, Kapoor G, Craig J, Balasubramanian R, Brar S. State of the world's antibiotics 2021: A global analysis of antimicrobial resistance and its drivers. Center for Disease Dynamics, Economics & Policy, Washington DC. 2021. Available at URL: <https://cddep.org/wp-content/uploads/2021/02/The-State-of-the-Worlds-Antibiotics-in-2021.pdf> [Accessed 23 September 2021]

Skosana PP, Schellack N, Godman B, Kurdi A, Bennie M, Kruger D, Meyer JC. A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications. *Expert Rev Anti Infect Ther.* 2021; 19(10):1353-1366. <https://doi.org/10.1080/14787210.2021.1898946>

Solis Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, Syunyaev G, Malik AA, Aboutajdine S, Adejo O, Anigo D, Armand A, Asad S, Atyera M, Augsburg B, Awasthi M, Ayesiga GE, Bancalari A, Björkman Nyqvist M, Borisova E, Bosancianu CM, Cabra García MR, Cheema A, Collins E, Cuccaro F, Farooqi AZ, Fatima T, Fracchia M, Galindo Soria ML, Guariso A, Hasanain A, Jaramillo S, Kallon S, Kamwesigye A, Kharel A, Kreps S, Levine M, Littman R, Malik M, Manirabaruta G, Mfura JLH, Momoh F, Mucauque A, Mussa I, Nsabimana JA, Obara I, Otálora MJ, Ouédraogo BW, Pare TB, Platas MR, Polanco L, Qureshi JA, Raheem M, Ramakrishna V, Rendrá I,

Shah T, Shaked SE, Shapiro JN, Svensson J, Tariq A, Tchiboza AM, Tiwana HA, Trivedi B, Vernot C, Vicente PC, Weissinger LB, Zafar B, Zhang B, Karlan D, Callen M, Teachout M, Humphreys M, Mobarak AM, Omer SB. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. *Nat Med.* 2021;27(8):1385-1394. <https://doi.org/10.1038/s41591-021-01454-y>

Sulis G, Batomen B, Kotwani A, Pai M, Gandra S. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. *PLoS Med.* 2021; 18(7):e1003682. <https://doi.org/10.1371/journal.pmed.1003682>

Swaminathan S, Prasad J, Dhariwal AC, Guleria R, Misra MC, Malhotra R, Mathur P, Walia K, Gupta S, Sharma A, Ohri V, Jain S, Gupta N, Laserson K, Malpiedi P, Velayudhan A, Park B, Srikantiah P. Strengthening infection prevention and control and systematic surveillance of healthcare associated infections in India. *BMJ.* 2017;358:j3768. <https://doi.org/10.1136/bmj.j3768>

Troisi M, Andreano E, Sala C, Kabanova A, Rappuoli R. Vaccines as remedy for antimicrobial resistance and emerging infections. *Curr Opin Immunol.* <https://doi.org/10.1016/j.coi.2020.09.003>

Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, Nathwani D, Goossens H; Global-PPS network. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. *Lancet Glob Health.* 2018;6(6):e619-e629. [https://doi.org/10.1016/S2214-109X\(18\)30186-4](https://doi.org/10.1016/S2214-109X(18)30186-4)

Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, Goyal JP, Tadepalli K, Mathur P, Venkateswaran R, Venkatasubramanian R, Khadanga S, Bhattacharya S, Mukherjee S, Baveja S, Sistla S, Panda S, Walia K. Secondary Infections in Hospitalized COVID-19 Patients: Indian Experience. *Infect Drug Resist.* 2021;14:1893-1903. <https://doi.org/10.2147/IDR.S299774>

Wilkinson A, Ebata A, MacGregor H. Interventions to Reduce Antibiotic Prescribing in LMICs: A Scoping Review of Evidence from Human and Animal Health Systems. *Antibiotics.* 2018; 22;8(1):2. <https://doi.org/10.3390/antibiotics8010002>

Wilson SL, Wiysonge C. Social media and vaccine hesitancy. *BMJ Glob Health.* 2020;5(10):e004206. <https://doi.org/10.1136/bmjgh-2020-004206>

Wojkowska-Mach J, Godman B, Glassman A, Kurdi A, Pilc A, Rozanska A, Skoczyński S, Wałaszek M, Bochenek T. Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. *Antimicrob Resist Infect Control.* 2018 Nov 15;7:136. <https://doi.org/10.1186/s13756-018-0428-8>

World Bank. Final Report - DRUG-RESISTANT INFECTIONS. A Threat to Our Economic Future March 2017. Available at URL: <http://documents1.worldbank.org/curated/en/323311493396993758/pdf/final-report.pdf>. [Accessed 23 September 2021]

World Health Organization. GLOBAL ACTION PLAN ON ANTIMICROBIAL RESISTANCE. 2015. Available at URL: [https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763\\_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1) [Accessed 23 September 2021]

World Health Organization. Technical Series on Primary Health Care. Antimicrobial resistance and primary health care. 2018. Available at URL: [https://www.who.int/docs/default-source/primary-health-care-conference/amr.pdf?sfvrsn=8817d5ba\\_2](https://www.who.int/docs/default-source/primary-health-care-conference/amr.pdf?sfvrsn=8817d5ba_2) [Accessed 24 September 2021]

World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. 4 July 2020. Available at URL: <https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19> [Accessed 23 September 2021]

### How to cite this article

Haque M., Meyer JC, Godman B. Potential ways to address antimicrobial resistance across India and wider exacerbated by COVID-19. *J App Pharm Sci*, 2021; 11 (10); 2021: i-vii.